Anivamersen

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Anivamersen
DrugBank Accession Number
DB16089
Background

Anivamersen is under investigation in clinical trial NCT01848106 (A Study to Determine the Efficacy and Safety of REG1 Compared to Bivalirudin in Patients Undergoing PCI).

Type
Small Molecule
Groups
Investigational
Structure
Thumb
Weight
Average: 4961.313
Monoisotopic: 4958.908624754
Chemical Formula
C157H208N56O103P14
Synonyms
  • Anivamersen
  • Rna, (cm-gm-cm-gm-gm-um-am-um-am-gm-um-cm-cm-am-cm)
External IDs
  • RB-007
  • RB007

Pharmacology

Indication

Not Available

Pharmacology
Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Contraindications
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Adverseeffects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
4OXU6KPQ3R
CAS number
959716-29-1
InChI Key
DJMVASRJWAOIAN-UHFFFAOYSA-N
InChI
InChI=1S/C157H208N56O103P14/c1-259-102-87(218)58(289-131(102)199-24-16-72(158)183-150(199)223)33-274-317(231,232)310-95-65(296-139(110(95)267-9)207-50-176-80-117(163)170-47-173-120(80)207)40-282-321(239,240)305-90-60(291-134(105(90)262-4)202-27-19-75(161)186-153(202)226)34-276-319(235,236)304-89-59(290-133(104(89)261-3)201-26-18-74(160)185-152(201)225)35-277-320(237,238)307-92-63(294-136(107(92)264-6)204-29-21-77(215)188-155(204)228)38-280-327(251,252)314-99-70(301-143(114(99)271-13)211-54-180-84-124(211)192-147(167)196-128(84)220)45-286-329(255,256)312-97-67(298-141(112(97)269-11)209-52-178-82-119(165)172-49-175-122(82)209)42-284-323(243,244)308-93-62(293-137(108(93)265-7)205-30-22-78(216)189-156(205)229)37-279-325(247,248)311-96-66(297-140(111(96)268-10)208-51-177-81-118(164)171-48-174-121(81)208)41-283-322(241,242)309-94-64(295-138(109(94)266-8)206-31-23-79(217)190-157(206)230)39-281-328(253,254)315-100-71(302-144(115(100)272-14)212-55-181-85-125(212)193-148(168)197-129(85)221)46-287-330(257,258)316-101-69(300-145(116(101)273-15)213-56-182-86-126(213)194-149(169)198-130(86)222)44-285-324(245,246)306-91-61(292-135(106(91)263-5)203-28-20-76(162)187-154(203)227)36-278-326(249,250)313-98-68(299-142(113(98)270-12)210-53-179-83-123(210)191-146(166)195-127(83)219)43-275-318(233,234)303-88-57(32-214)288-132(103(88)260-2)200-25-17-73(159)184-151(200)224/h16-31,47-71,87-116,131-145,214,218H,32-46H2,1-15H3,(H,231,232)(H,233,234)(H,235,236)(H,237,238)(H,239,240)(H,241,242)(H,243,244)(H,245,246)(H,247,248)(H,249,250)(H,251,252)(H,253,254)(H,255,256)(H,257,258)(H2,158,183,223)(H2,159,184,224)(H2,160,185,225)(H2,161,186,226)(H2,162,187,227)(H2,163,170,173)(H2,164,171,174)(H2,165,172,175)(H,188,215,228)(H,189,216,229)(H,190,217,230)(H3,166,191,195,219)(H3,167,192,196,220)(H3,168,193,197,221)(H3,169,194,198,222)
IUPAC Name
{[(2R,3R,4R,5R)-2-{[({[(2R,3R,4R,5R)-5-(4-amino-2-oxo-1,2-dihydropyrimidin-1-yl)-2-{[({[(2R,3R,4R,5R)-5-(4-amino-2-oxo-1,2-dihydropyrimidin-1-yl)-2-{[({[(2R,3R,4R,5R)-2-{[({[(2R,3R,4R,5R)-2-{[({[(2R,3R,4R,5R)-2-{[({[(2R,3R,4R,5R)-2-{[({[(2R,3R,4R,5R)-2-{[({[(2R,3R,4R,5R)-2-{[({[(2R,3R,4R,5R)-2-{[({[(2R,3R,4R,5R)-2-{[({[(2R,3R,4R,5R)-5-(4-amino-2-oxo-1,2-dihydropyrimidin-1-yl)-2-{[({[(2R,3R,4R,5R)-2-{[({[(2R,3R,4R,5R)-5-(4-amino-2-oxo-1,2-dihydropyrimidin-1-yl)-2-(hydroxymethyl)-4-methoxyoxolan-3-yl]oxy}(hydroxy)phosphoryl)oxy]methyl}-5-(2-amino-6-oxo-6,9-dihydro-1H-purin-9-yl)-4-methoxyoxolan-3-yl]oxy}(hydroxy)phosphoryl)oxy]methyl}-4-methoxyoxolan-3-yl]oxy}(hydroxy)phosphoryl)oxy]methyl}-5-(2-amino-6-oxo-6,9-dihydro-1H-purin-9-yl)-4-methoxyoxolan-3-yl]oxy}(hydroxy)phosphoryl)oxy]methyl}-5-(2-amino-6-oxo-6,9-dihydro-1H-purin-9-yl)-4-methoxyoxolan-3-yl]oxy}(hydroxy)phosphoryl)oxy]methyl}-5-(2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-yl)-4-methoxyoxolan-3-yl]oxy}(hydroxy)phosphoryl)oxy]methyl}-5-(6-amino-9H-purin-9-yl)-4-methoxyoxolan-3-yl]oxy}(hydroxy)phosphoryl)oxy]methyl}-5-(2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-yl)-4-methoxyoxolan-3-yl]oxy}(hydroxy)phosphoryl)oxy]methyl}-5-(6-amino-9H-purin-9-yl)-4-methoxyoxolan-3-yl]oxy}(hydroxy)phosphoryl)oxy]methyl}-5-(2-amino-6-oxo-6,9-dihydro-1H-purin-9-yl)-4-methoxyoxolan-3-yl]oxy}(hydroxy)phosphoryl)oxy]methyl}-5-(2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-yl)-4-methoxyoxolan-3-yl]oxy}(hydroxy)phosphoryl)oxy]methyl}-4-methoxyoxolan-3-yl]oxy}(hydroxy)phosphoryl)oxy]methyl}-4-methoxyoxolan-3-yl]oxy}(hydroxy)phosphoryl)oxy]methyl}-5-(6-amino-9H-purin-9-yl)-4-methoxyoxolan-3-yl]oxy}({[(2R,3R,4R,5R)-5-(4-amino-2-oxo-1,2-dihydropyrimidin-1-yl)-3-hydroxy-4-methoxyoxolan-2-yl]methoxy})phosphinic acid
SMILES
COC1C(OP(O)(=O)OCC2OC(C(OC)C2O)N2C=CC(N)=NC2=O)C(COP(O)(=O)OC2C(COP(O)(=O)OC3C(COP(O)(=O)OC4C(COP(O)(=O)OC5C(COP(O)(=O)OC6C(COP(O)(=O)OC7C(COP(O)(=O)OC8C(COP(O)(=O)OC9C(COP(O)(=O)OC%10C(COP(O)(=O)OC%11C(COP(O)(=O)OC%12C(COP(O)(=O)OC%13C(COP(O)(=O)OC%14C(CO)OC(C%14OC)N%14C=CC(N)=NC%14=O)OC(C%13OC)N%13C=NC%14=C%13N=C(N)NC%14=O)OC(C%12OC)N%12C=CC(N)=NC%12=O)OC(C%11OC)N%11C=NC%12=C%11N=C(N)NC%12=O)OC(C%10OC)N%10C=NC%11=C%10N=C(N)NC%11=O)OC(C9OC)N9C=CC(=O)NC9=O)OC(C8OC)N8C=NC9=C8N=CN=C9N)OC(C7OC)N7C=CC(=O)NC7=O)OC(C6OC)N6C=NC7=C6N=CN=C7N)OC(C5OC)N5C=NC6=C5N=C(N)NC6=O)OC(C4OC)N4C=CC(=O)NC4=O)OC(C3OC)N3C=CC(N)=NC3=O)OC(C2OC)N2C=CC(N)=NC2=O)OC1N1C=NC2=C1N=CN=C2N

References

General References
Not Available
ChemSpider
67161741

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3TerminatedTreatmentCoronary Artery Disease (CAD)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
logP-18ChemAxon
pKa (Strongest Acidic)0.93ChemAxon
Physiological Charge-12ChemAxon
Hydrogen Acceptor Count109ChemAxon
Hydrogen Donor Count35ChemAxon
Polar Surface Area2089.74 Å2ChemAxon
Rotatable Bond Count101ChemAxon
Refractivity1049.07 m3·mol-1ChemAxon
Polarizability430.45 Å3ChemAxon
Number of Rings37ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Drug created on December 15, 2020 18:04 / Updated on February 21, 2021 18:55